title: [A case of Chinese herbs nephropathy in which the progression of renal dysfunction was slowed by steroid therapy].
abstract: The patients was a 43-year-old woman whose chief complaints were nausea and heaviness of the heads. There was a history of toxemia of pregnancy. The patient had previously taken Tenshin Tokishigyaku-ka-goshuyu-shokyo-to for two years because of cold sensitivity. Fever, thirst, and loss of appetite developed from approximately 18 months after she started treatment with the Chinese herbal preparation, and she presented at our outpatient clinic 2.5 years later. On initial examination, deterioration of renal function was evident and the serum creatinine level was 3.4 mg/dl. A renal biopsy specimen showed marked interstitial fibrosis without inflammatory cell infiltration, leading to the diagnosis of Chinese herbs nephropathy (CHN). Steroid therapy was started on the 36th hospital day after a sharp rise in the serum creatinine level to 5.1 mg/dl. This resulted in the rapid improvement of renal function and reduction of the serum creatinine to 2.6 mg/dl by 8 weeks after the initiation of treatment. In a study on the use of steroids for patients with progressive moderate renal dysfunction caused by Chinese herbs, Vanherweghem et al. reported that the progression of renal failure was appreciably slowed in patients given steroids when compared with the control group. We were also able to slow the progression of renal dysfunction in our patient by steroid therapy, although the prognosis of CHN is generally considered to be very poor.
authors.affiliation: Department of Nephrology, Fujita Health University School of Medicine, Aichi, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Yoshimura
authors.forename: M
authors.initials: M
authors.lastname: Fujii
authors.forename: S
authors.initials: S
authors.lastname: Koide
authors.forename: M
authors.initials: M
authors.lastname: Murase
authors.forename: S
authors.initials: S
authors.lastname: Asano
authors.forename: T
authors.initials: T
authors.lastname: Toba
authors.forename: H
authors.initials: H
authors.lastname: Yoshikawa
authors.forename: H
authors.initials: H
authors.lastname: Kushimoto
authors.forename: H
authors.initials: H
authors.lastname: Katsumata
authors.forename: K
authors.initials: K
authors.lastname: Murakami
authors.forename: M
authors.initials: M
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Tomita
authors.forename: H
authors.initials: H
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Shikano
authors.forename: S
authors.initials: S
authors.lastname: Kawashima
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004365:Drugs, Chinese Herbal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004365:Drugs, Chinese Herbal; D011239:Prednisolone